Olema Pharmaceuticals, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 26.18 million compared to USD 21.64 million a year ago. Basic loss per share from continuing operations was USD 0.65 compared to USD 0.54 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.645 USD | +4.27% | +4.72% | -31.25% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.25% | 517M | |
+48.67% | 58.71B | |
-2.76% | 41.31B | |
+36.42% | 39.2B | |
-11.22% | 27.4B | |
+9.25% | 26.55B | |
-23.10% | 18.98B | |
+1.88% | 12.51B | |
+26.43% | 12.08B | |
+21.74% | 11.94B |
- Stock Market
- Equities
- OLMA Stock
- News Olema Pharmaceuticals, Inc.
- Olema Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022